Delayed cytokine release syndrome after neoadjuvant nivolumab: a case report and literature review.
Immunotherapy
; 13(13): 1071-1078, 2021 09.
Article
en En
| MEDLINE
| ID: mdl-34287029
Lay abstract Aim: Cytokine release syndrome (CRS) is a rare but potentially serious side effect of a class of immunotherapy drugs called checkpoint inhibitors (CPI). CRS typically presents with fevers and low blood pressure and can cause damage to organs including the kidneys and liver. Case study: We report an unusual case of severe CRS occurring after surgery in a patient who had received prior CPI therapy. After a thorough evaluation for alternative causes, he was diagnosed with CRS and treated successfully with steroids. Conclusion: It is important for medical providers to consider this potential side effect when treating patients with CPI. Further research is needed to clarify the role of surgery in CPI-induced CRS.
Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Complicaciones Posoperatorias
/
Neoplasias Colorrectales
/
Síndrome de Liberación de Citoquinas
/
Inhibidores de Puntos de Control Inmunológico
/
Inmunoterapia
Límite:
Aged
/
Humans
/
Male
Idioma:
En
Revista:
Immunotherapy
Asunto de la revista:
ALERGIA E IMUNOLOGIA
/
TERAPEUTICA
Año:
2021
Tipo del documento:
Article
País de afiliación:
Estados Unidos